This story originally ran on March 2.
Advanced Proteome Therapeutics said this week that the European Patent Office "intends" to grant a patent covering the company's method for site-specifically modifying proteins.
According to a statement from APT, site-specific modifications are often necessary to prepare proteins for commercial use, and the method developed by the company is for discovering novel protein sites for attaching entities to enhance the properties of proteins.
"The method consists of ensembles of specially designed molecules that are in competition to selectively modify protein molecules," APT said. "The winning molecules are detected by their greater abundance at specific target sites."
Potential applications for the method include the creation of "entirely new classes of therapeutic proteins" and new versions of off-patent proteins.
In the fall, APT filed a patent application with the US Patent and Trademark Office and under the Patent Cooperation Treaty pertaining to a related technology to attach an agent to the protein [See PM 10/30/09].
Based in Vancouver, British Columbia, APT develops technology to modify proteins for therapeutic and industrial uses.